Jamp Fenofibrate E Product Monograph

Recent Major Label Changes

N/A

Table of Contents

Certain sections or subsections that are not applicable at the time of the preparation of the most recent authorized product monograph are not listed.

Recent Major Label Changes ................................................................................................... 2

Table of Contents .................................................................................................................... 2

Part 1: Healthcare Professional Information ........................................................................... 4

1. 1.

   Indications .............................................................................................................................. 4

   1. 1.1. Pediatrics .................................................................................................................. 4
   2. 1.2. Geriatrics .................................................................................................................. 4
2. 2. Contraindications ................................................................................................................... 4
3. 4.

   Dosage and Administration ................................................................................................... 5

   1. 4.1. Dosing Considerations .............................................................................................. 5
   2. 4.2. Recommended Dose and Dosage Adjustment .......................................................... 5
   3. 4.4. Administration .......................................................................................................... 6
   4. 4.5. Missed Dose .............................................................................................................. 6
4. 5. Overdose ................................................................................................................................ 6
5. 6. Dosage Forms, Strengths, Composition, and Packaging ....................................................... 6
6. 7.

   Warnings and Precautions ..................................................................................................... 7

   General ................................................................................................................................. 7

   Carcinogenesis and Genotoxicity .......................................................................................... 7

   Hematologic .......................................................................................................................... 8

   Hepatic/Biliary/Pancreatic ..................................................................................................... 8

   Monitoring and Laboratory Tests .......................................................................................... 8

   Musculoskeletal .................................................................................................................... 8

   Renal ..................................................................................................................................... 9

   Reproductive Health ............................................................................................................. 9

   1. 7.1.

      Special Populations ................................................................................................... 9

      1. 7.1.1. Pregnancy ......................................................................................................... 9
      2. 7.1.2. Breastfeeding .................................................................................................. 10
      3. 7.1.3. Pediatrics ........................................................................................................ 10
      4. 7.1.4. Geriatrics......................................................................................................... 10
7. 8.

   Adverse Reactions ................................................................................................................ 10

   1. 8.1. Adverse Reaction Overview .................................................................................... 10
   2. 8.2. Clinical Trial Adverse Reactions .............................................................................. 10
   3. 8.3. Less Common Clinical Trial Adverse Reactions ........................................................ 14

8.5. Post-Market Adverse Reactions .............................................................................. 14

1. 9.

   Drug Interactions .................................................................................................................. 15

   1. 9.2. Drug Interactions Overview .................................................................................... 15
   2. 9.3. Drug-Behaviour Interactions ................................................................................... 15
   3. 9.4. Drug-Drug Interactions ........................................................................................... 15
   4. 9.5. Drug-Food Interactions ........................................................................................... 19
   5. 9.6. Drug-Herb Interactions ........................................................................................... 19
   6. 9.7. Drug-Laboratory Test Interactions .......................................................................... 19
2. 10.

   Clinical Pharmacology .......................................................................................................... 19

   1. 10.1. Mechanism of Action .............................................................................................. 19
   2. 10.2. Pharmacodynamics ................................................................................................. 19
   3. 10.3. Pharmacokinetics .................................................................................................... 21
3. 11. Storage, Stability, and Disposal ............................................................................................ 22

Part 2: Scientific Information ................................................................................................ 23

1. 13. Pharmaceutical Information ................................................................................................ 23
2. 14.

   Clinical Trials ......................................................................................................................... 23

   1. 14.1. Clinical Trials by Indication ...................................................................................... 23
   2. 14.2. Comparative Bioavailability Studies ........................................................................ 27
3. 16. Non-Clinical Toxicology ........................................................................................................ 31
4. 17. Supporting Product Monographs…………………………………………………………………………………..34

Patient Medication Information ............................................................................................ 35

Part 1: Healthcare Professional Information

1. Indications

JAMP Fenofibrate E (fenofibrate) is indicated as an adjunct to diet, at least equivalent to the Adults Treatment Panel III (ATP III) and Therapeutic Lifestyle Changes (TLC diet), and other therapeutic measures when the response to diet and other measures has been inadequate for:

• Treatment of patients, including patients with type 2 diabetes (non-insulin dependent), with dyslipoproteinemia (hypercholesterolemia, Fredrickson classification Types IIa and IIb mixed hyperlipidemia), to regulate lipid levels by reducing serum triglycerides and LDL cholesterol levels and increasing HDL cholesterol.
• Treatment of adult patients with very high serum triglyceride levels, Fredrickson classification Type IV and Type V hyperlipidemia, who are at a high risk of sequelae and complications (i.e., pancreatitis) from their hyperlipidemia.

JAMP Fenofibrate E, administered in combination with ezetimibe, is indicated for the reduction of elevated total-C, LDL-C, Apo B, and non HDL-C in patients with mixed hyperlipidemia.

JAMP Fenofibrate E alone may not be adequate therapy in some patients with familial combined hyperlipidemia with Type IIb and Type IV hyperlipoproteinemia.

JAMP Fenofibrate E is not indicated for the treatment of Type I hyperlipoproteinemia.

1.1. Pediatrics

Pediatrics (< 18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of fenofibrate in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use. See 7.1.3 Pediatrics.

1.2. Geriatrics

Geriatrics (≥65 years of age): Evidence from clinical studies suggests that use in the geriatric population is not associated with significant differences in safety or efficacy.

2. Contraindications

JAMP Fenofibrate E is contraindicated for:

• Patients who are hypersensitive to fenofibrate or to any ingredients in the formulation of components of the container including peanut or arachis oil or soya lecithin or related products. For complete listing, see the 6 Dosage Forms, Strengths, Composition, and Packaging.
• Patients with hepatic insufficiency (including primary biliary cirrhosis and unexplained persistent liver function abnormality).
• Patients with pre-existing gallbladder disease (see 7 Hepatic/Biliary/Pancreatic).
• Patients with severe renal dysfunction (creatinine clearance < 30ml/min).
• Patients with chronic or acute pancreatitis.
• Pregnant and breast-feeding women.
• Patients with known photoallergy or phototoxic reaction during treatment with fibrates or ketoprofen.
• Co-administration with HMG-CoA reductase inhibitors (statins) in patients with pre-disposing factors for myopathy.

4. Dosage and Administration

4.1. Dosing Considerations

• Patients should be placed on a standard cholesterol-lowering diet (at least equivalent to the Adult Treatment Panel III (ATP III TLC diet)) before receiving JAMP Fenofibrate E (fenofibrate), and should continue on this diet during treatment with JAMP Fenofibrate E. If appropriate, a program of weight control and physical exercise should be implemented.
• Prior to initiating therapy with JAMP Fenofibrate E, secondary causes for elevations in plasma lipid levels should be excluded. A lipid profile should also be performed.
• If a significant serum lipid response is not obtained in three months, JAMP Fenofibrate E should be discontinued.

4.2. Recommended Dose and Dosage Adjustment

• The usual recommended dose for JAMP Fenofibrate E in adults, is one 145 mg tablet daily, taken any time with or without food. Tablets should be swallowed whole with a glass of water. In the elderly, the initial dose should be limited to 48 mg per day. The dose should be individualized according to patient response and should be adjusted if necessary following repeat lipid determinations.
• The maximum recommended daily dose of JAMP Fenofibrate E is 145 mg.
• In patients having impaired renal function, treatment with JAMP Fenofibrate E should be initiated at a dose of 48 mg per day and increased only after evaluation of the effects on renal function and lipid levels at this dose.
• JAMP Fenofibrate E can be taken in combination with ezetimibe 10 mg once daily orally with or without food, preferably at the same time each day.
• Initial Therapy: Before instituting fenofibrate therapy, laboratory tests should be conducted to ensure that lipid levels are consistently abnormal. Attempts should be made to control serum lipids with appropriate diet, exercise and weight loss in obese patients. Secondary causes of hypercholesterolemia, such as uncontrolled type 2 diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemia, obstructive liver disease, pharmacological treatment and excessive alcohol intake should be adequately treated before fenofibrate therapy is initiated. In patients at high risk, consideration should be given to the control of other risk factors such as smoking, use of preparations containing estrogen and inadequately controlled hypertension.
• Long-term therapy: Because long-term administration of fenofibrate is recommended, the potential risks and benefits should be carefully weighed. Adequate pretreatment laboratory studies should be performed to ensure that patients have elevated serum cholesterol and/or triglycerides or low HDL-cholesterol levels.

• Response to therapy should be monitored by determination of serum lipid values (e.g. total

  cholesterol, LDL-C, triglycerides). If a significant serum lipid response is not obtained in three months, JAMP Fenofibrate E should be discontinued.

• JAMP Fenofibrate E is not recommended for use in patients with hepatic impairment due to the lack of data.
• JAMP Fenofibrate E should not be used in patients with severe renal dysfunction including patients on dialysis.

4.4. Administration

Tablets can be taken any time with or without food and should be swallowed whole (not crushed or chewed) with a glass of water.

4.5. Missed Dose

If a dose is missed, the next dose should be taken at the usual time. A double dose should not be taken to make up for a forgotten dose.

5. Overdose

While there has been no reported case of overdosage, symptomatic and supportive measures should be taken. Fenofibrate is not dialysable because the main metabolite (fenofibric acid) is highly bound to plasma proteins.

For the most recent information in the management of a suspected drug overdose, contact your regional poison control centre or Health Canada’s toll-free number, 1-844 POISON-X (1-844-764-7669).

1. 6. Dosage Forms, Strengths, Composition, and Packaging

Table 1 – Dosage Forms, Strengths, and Composition

Availability

JAMP Fenofibrate E (fenofibrate) film-coated tablets are formulated for oral administration containing fenofibrate and are available in two strengths: 48 mg and 145 mg.

Composition

JAMP Fenofibrate E 48 mg tablets are supplied as yellow-coloured, biconvex, oval-shaped, film-coated tablets, debossed with “48” on one side and “FT” on the other side. The tablets are available in bottles of 90 and 100 tablets and blister packs of 30 tablets.

JAMP Fenofibrate E 145 mg tablets are supplied as white-coloured, biconvex, oval-shaped, film-coated tablets, debossed with “F145” on one side and plain on other side. The tablets are available in bottles of 90 and 100 tablets and blister packs of 30 tablets.

7. Warnings and Precautions

General

Fenofibrate and HMG-CoA Reductase Inhibitors (Statins)

The concomitant administration of JAMP Fenofibrate E (fenofibrate) and statins should be avoided unless the benefit for further alteration in lipid levels is likely to outweigh the increased risk of this combination.

The combined use of fibric acid derivatives and HMG-CoA reductase inhibitors has been associated, in the absence of a marked pharmacokinetic action, in numerous case reports, with rhabdomyolysis, severe myositis, markedly elevated creatine kinase (CK) levels and myoglobinuria, leading to a high proportion of cases to acute renal failure.

This combination therapy must not be used in patients with predisposing factors for myopathy (pre-existing myopathy, age >70 years, renal impairment, hepatic impairment, severe infection, surgery and trauma, frailty, hypothyroidism or electrolyte imbalance, personal or family history of hereditary muscular disorders, previous history of muscle toxicity with another HMG-CoA reductase inhibitor, concomitant use of a fibrate, niacin or ezetimibe, alcohol abuse, excessive physical exercise, diabetes with hepatic fatty change situations where an increase in plasma levels of active ingredient may occur).

For information on a specific HMG-CoA reductase inhibitor, consult a respective Product Monograph.

Concomitant administration with ezetimibe: When JAMP Fenofibrate E (fenofibrate) is to be administered with ezetimibe, the ezetimibe Product Monograph should be consulted. The co-administration of ezetimibe with fibrates other than fenofibrate has not been studied. Therefore, co-administration of ezetimibe and fibrates other than fenofibrate is not recommended (see 9.4 Drug-Drug Interactions, and Product Monograph for ezetimibe).

Carcinogenesis and Genotoxicity

In long-term animal toxicity and carcinogenicity studies, fenofibrate has been shown to be tumorigenic for the in benign Leydig cell tumors. Pancreatic acinar cell tumors were increased in male rats at 9 and 40 times the human dose. However, mice and female rats were unaffected at similar doses. Florid hepato-cellular liver in male rats at 12 times the human dose. At this dose level in male rats there was also an increase peroxisome proliferation has been observed following fenofibrate administration to rats (see 16 Non-Clinical Toxicology, Carcinogenicity). Such changes have not been found in the human liver after up to 3.5 years of fenofibrate administration.

Hematologic

Mild hemoglobin, haematocrit and white blood cell decreases have been observed occasionally in patients following initiation of fenofibrate therapy. However, these levels stabilize during long-term administration. Periodic blood counts are recommended during the first 12 months of fenofibrate administration.

Hepatic/Biliary/Pancreatic

Fenofibrate may increase cholesterol excretion into the bile, and may lead to cholelithiasis.

If cholelithiasis is suspected in a patient receiving ezetimibe and JAMP Fenofibrate E, gallbladder studies are indicated and alternative lipid-lowering therapy should be considered (see 8 Adverse Reactions).

Pancreatitis: In common with some other fibrates, pancreatitis has been reported in patients taking fenofibrate. This occurrence may represent a failure of efficacy in patients with severe hypertriglyceridemia, a direct drug effect, or a secondary phenomenon mediated through biliary tract stone or sludge formation with obstruction of the common bile duct. In patients with severe hypertriglyceridemia, cases of acute pancreatitis have been reported.

Cholelithiasis: Fenofibrate may increase cholesterol excretion into the bile, and may lead to cholelithiasis. If cholelithiasis is suspected, gallbladder studies are indicated. JAMP Fenofibrate E therapy should be discontinued if gallstones are found.

Monitoring and Laboratory Tests

Abnormal liver function tests have occasionally been observed during fenofibrate administration, including elevations of transaminases, and decreases or, rarely, increases in alkaline phosphatase. From 5 placebo-controlled trials of 2 to 6 months’ duration, increases up to >3 times the upper limit of normal occurred in 2.9% (14/477) of patients taking fenofibrate versus 0.5% (2/386) of those treated with placebo. In the DAIS study (3 years duration), increases up to 3 times the upper limit of normal occurred in 1.9% (4/207) of patients taking fenofibrate versus 0% of those treated with placebo (0/211). Follow-up measurements, performed either at the end of treatment or during continued treatment, showed that transaminase values generally returned to normal limits. Therefore, regular periodic liver function tests (AST, ALT and GGT) in addition to other baseline tests are recommended every 3 months for the first 12 months and at least yearly thereafter. JAMP Fenofibrate E should be discontinued if abnormalities persist and / or AST and ALT levels increase to more than 3 times the upper limit of normal.

Concomitant administration with ezetimibe: When ezetimibe is initiated in a patient already taking JAMP Fenofibrate E, liver function tests should be considered at initiation of ezetimibe therapy and then as indicated. When ezetimibe is initiated at the same time as JAMP Fenofibrate E, liver function tests should be performed at initiation of therapy according to the above recommendations (see 8 Adverse Reactions).

Musculoskeletal

The use of fibrates alone, including JAMP Fenofibrate E, may occasionally be associated with myositis, myopathy or rhabdomyolysis, usually in patients with impaired renal function and in cases of hypoalbuminemia. Patients receiving JAMP Fenofibrate E should be advised to promptly report diffuse myalgias/muscle pain, muscle cramps, tenderness, or weakness, particularly if accompanied by malaise or fever. They should have prompt medical evaluation for myopathy, including serum creatine phosphokinase level determination. If markedly elevated CK levels (5 times the upper limit of normal), myopathy and or myositis is suspected or diagnosed, JAMP Fenofibrate E therapy should be stopped.

Patients with pre-disposing factors for myopathy may be at an increased risk of developing rhabdomyolysis (see 7 General, Fenofibrate and HMG-CoA Reductase Inhibitors (Statins)). For these patients, the putative benefits and risks of fenofibrate therapy should be carefully weighed.

The risk of muscle toxicity may be increased if the drug is administered with another fibrate or an HMG-CoA reductase inhibitor, especially in case of pre-existing muscular disease (see 7 General, Fenofibrate and HMG-CoA Reductase Inhibitors (Statins)). Consequently, the co-administration of fenofibrate with a HMG-CoA reductase inhibitor or another fibrate should be reserved to patients with severe combined dyslipidemia and high cardiovascular risk without any history of muscular disease or other pre-disposing factors for myopathy (see 7 General, Fenofibrate and HMG-CoA Reductase Inhibitors (Statins)) and with a close monitoring of potential muscle toxicity.

Post marketing reports of adverse events have included rare cases of myopathy/rhabdomyolysis occurring in patients taking ezetimibe. Myopathy/ rhabdomyolysis should be considered in patients presenting with muscle pain during treatment with ezetimibe and JAMP Fenofibrate E, and consideration given to discontinuation of the drugs. Most cases of myopathy/rhabdomyolysis resolved when drugs were discontinued.

Renal

In patients with hypoalbuminemia, e.g., nephrotic syndrome, and in patients with renal insufficiency, the dosage of fenofibrate must be reduced and renal function should be monitored regularly (see 7 Skeletal Muscle, 4 Dosage and Administration, and 10 Clinical Pharmacology).

Treatment should be interrupted in case of an increase in creatinine level > 50% upper limit of normal. It is recommended that creatinine measurement may be considered during the first three months after initiation of treatment.

Reproductive Health

Standard tests for teratology, fertility and peri- and post-natal effects in animals have shown a relative absence of risk; however, embryo-toxicity has occurred in animals at maternally toxic doses (see 16 Non-Clinical Toxicology).

7.1. Special Populations

7.1.1. Pregnancy

Safety in pregnant women has not been established. Fenofibrate has been shown to be embryocidal in rats when given in doses 7 to 10 times the maximum recommended human dose (MRHD) and in rabbits when given in doses 9 times the MRHD (on the basis of mg/m² surface area). There are no adequate and well-controlled studies in pregnant women. Fenofibrate should not be used during pregnancy (see 16 Non-Clinical Toxicology).

7.1.2. Breastfeeding

It is unknown whether fenofibrate and/or its metabolites are excreted in human milk. A risk to the suckling child cannot be excluded. Therefore JAMP Fenofibrate E should not be used during breast-feeding (see 16 Non-Clinical Toxicology).

7.1.3. Pediatrics

Pediatrics (< 18 years of age): No data are available to Health Canada to establish the safety and efficacy of fenofibrate in children and adolescents younger than 18 years. Therefore, Health Canada has not authorized an indication for pediatric use.

7.1.4. Geriatrics

Geriatrics (>65 years of age): Fenofibrate is excreted by the kidney. Therefore, the risk of adverse reactions to fenofibrate may be greater in the elderly patients with impaired renal function. Since elderly patients are more likely to have a decreased renal function, dose should be carefully selected (see 4 Dosage and Administration).

8. Adverse Reactions

8.1. Adverse Reaction Overview

The most frequently reported adverse events include: gastrointestinal (epigastric distress, flatulence, abdominal pain, nausea, diarrhea, constipation), dermatologic (erythema, pruritus, urticaria), musculoskeletal (muscle pain and weakness, arthralgia), central nervous system (headache, dizziness, insomnia), miscellaneous (decreased libido, hair loss, weight loss).

8.2. Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. Therefore, the frequencies of adverse reactions observed in the clinical trials may not reflect frequencies observed in clinical practice and should not be compared to frequencies reported in clinical trials of another drug.

In five placebo-controlled clinical trials, conducted in the U.S. and Europe, a total of 477 patients on fenofibrate and 386 patients on placebo were evaluated for adverse effects during 2 to 6 months of treatment.

Adverse events led to the withdrawal of treatment in 5.5% of patients (26/477) treated with fenofibrate, the most common symptoms being abnormal elevation in transaminases, skin reactions and digestive disorders. Of the placebo-treated patients, 2.6% (10/386) were discontinued due to adverse effects.

Adverse events, regardless of their causality, reported in more than 1% of patients are shown in Table 2.

Table 2 – Number (%) of Patients Reporting Adverse Events

Safety was monitored for 3 years during the placebo-controlled DAIS study (see 14 Clinical Trials) for both adverse events and laboratory anomalies. Fenofibrate was used safely in type 2 diabetic patients, as the overall incidence and severity of adverse events were comparable in fenofibrate and placebo groups. Table 3 below summarizes the incidence of adverse events, by body system, observed in both treatment groups.

Table 3 – DAIS study: Incidence of adverse events (AEs) by system, experienced by type 2 diabetic patients during treatment with fenofibrate or placebo (ITT population)

In two open, non-controlled clinical studies conducted in Canada and Germany, a total of 375 patients on fenofibrate, microcoated formulation, were evaluated for adverse events. Listed in Table 4 are the adverse events possibly or probably related to fenofibrate, microcoated formulation and reported by more than 0.5% of the patients.

Table 4 – Number (%) of Patients Reporting Adverse Events Possibly or Probably Related to Fenofibrate

Some epidemiological studies and case reports support paradoxical HDL-C lowering with fenofibrate.

Other adverse events include commonly reported cases of vomiting and increase in levels of blood homocysteine*. Uncommonly reported cases of pancreatitis and venous thromboembolism (pulmonary embolism and deep vein thrombosis). Rarely reported cases of alopecia, sexual asthenia, rhabdomyolysis, myositis and muscular cramps. Episodes of hepatitis have been reported. When symptoms indicative of hepatitis occur (e.g. jaundice, pruritus), and diagnosis is confirmed by laboratory testing, fenofibrate therapy should be discontinued (see 7 Monitoring and Laboratory Tests).

Photosensitivity reactions, development of gallstones and cutaneous hypersensitivity with erythema and vesiculation or nodulation on parts of the skin exposed to sunlight or artificial UV light in individual cases (even after many months of uncomplicated use) have also been reported.

* The average increase in blood homocysteine level in patients treated with fenofibrate was 6.5

μmol/L, and was reversible on discontinuation of fenofibrate treatment. The increased risk of venous thrombotic events may be related to the increased homocysteine level. The clinical significance of this is not clear.

Combination with ezetimibe:

When JAMP Fenofibrate E (fenofibrate) is to be administered with ezetimibe, the ezetimibe Product Monograph should also be consulted.

In a clinical study involving 625 patients treated for up to 12 weeks and 576 patients treated for up to 1 year, co-administration of fenofibrate and ezetimibe was well tolerated. This study was not designed to compare treatment groups for infrequent events. Incidence rates (95% CI) for clinically important elevations (>3 ULN, consecutive) in serum transaminases were 4.5% (1.9, 8.8) and 2.7% (1.2, 5.4) for fenofibrate monotherapy and ezetimibe co-administered with fenofibrate, respectively, adjusted for treatment exposure. Corresponding incidence rates for cholecystectomy were 0.6% (0.0, 3.1) and 1.7% (0.6, 0.4) for fenofibrate monotherapy and ezetimibe co-administered with fenofibrate, respectively (see 9.4 Drug-Drug Interactions). There were no CPK elevations > 10X ULN in either treatment group in this study. No cases of myopathy, rhabdomyolysis, or pancreatitis were reported in this 12 weeks study.

8.3. Less Common Clinical Trial Adverse Reactions

See Table 4.

8.5. Post-Market Adverse Reactions

In addition to those events reported during clinical trials, the following side effects have been reported spontaneously during post-marketing use:

Respiratory, thoracic and mediastinal disorders: Interstitial lung disease.

Hepatobiliary Disorders: jaundice, complications of cholelithiasis (e.g., cholecystitis, cholangitis, biliary colic, etc.)

Skin and Subcutaneous Tissue Disorders: severe cutaneous reactions (e.g erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis)

Nervous system disorders: Fatigue

9. Drug Interactions

9.2. Drug Interactions Overview

Fenofibrate is highly protein bound (>99%), mainly to albumin. Consideration should be given to the potential for displacement drug interactions with other highly protein-bound drugs.

9.3. Drug-Behaviour Interactions

The interaction of fenofibrate with individual behavioural risks (e.g. cigarette smoking, cannabis use, and/or alcohol consumption) has not been studied.

9.4. Drug-Drug Interactions

No drug-drug interaction studies with fenofibrate and statins have been conducted in patients. Pharmacokinetic interaction studies conducted with drugs in healthy subjects may not detect the possibility of a potential drug interaction in some patients due to differences in underlying disease and use of concomitant medications (see 7 General, Fenofibrate and HMG-CoA Reductase Inhibitors

(Statins)).

The drugs listed in this table are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction (i.e., those identified as contraindicated).

Table 5 – Established or Potential Drug-Drug Interactions

Legend: C = Case Study; CT = Clinical Trial; P = Potential

9.5. Drug-Food Interactions

Interactions with food have not been established.

9.6. Drug-Herb Interactions

Interactions with herbal products have not been established.

9.7. Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

1. 10. Clinical Pharmacology

10.1. Mechanism of Action

JAMP Fenofibrate E (fenofibrate) lowers elevated serum lipids by decreasing the low-density lipoprotein (LDL) fraction rich in cholesterol and the very low-density lipoprotein (VLDL) fraction rich in triglycerides. In addition, fenofibrate increases the high-density lipoprotein (HDL) cholesterol fraction.

Fenofibrate appears to have a greater depressant effect on the VLDL than on the low-density lipoproteins (LDL). Therapeutic doses of fenofibrate produce elevations of HDL cholesterol, a reduction in the content of the low-density lipoprotein cholesterol, and a substantial reduction in the triglyceride content of VLDL.

10.2. Pharmacodynamics

Fenofibrate is a fibric acid derivative whose lipid modifying effects reported in humans are mediated by the activation of a specific nuclear receptor called peroxisome proliferator activated receptor alpha

(PPARα), which produces:

• a reduction in apo C-III, and therefore a reduction in the level of dense atherogenic LDL particles;
• a stimulation of mitochondrial beta-oxidation, and therefore a reduction in triglyceride secretion;
• a rise in lipoprotein lipase production, and therefore an acceleration of triglyceride rich lipoprotein breakdown;
• a rise in apo A-I and apo A-II production.

Animal Pharmacology

The antilipidemic activity of fenofibrate was investigated in normal and hyperlipidemic rats. Fenofibrate significantly lowers total lipids, LDL and VLDL cholesterol, and triglyceride levels. At the same time it has been found to variably increase HDL cholesterol concentrations. Its effect is more pronounced in hyperlipidemic rats and those fed high fat diets than in normal rats and those fed standard diets. Studies comparing fenofibrate with clofibrate have found that fenofibrate is a potent cholesterol-lowering drug.

The pronounced hypolipidemic effect in hyperlipidemic animals suggests that fenofibrate reduces cholesterol by enhancing the rate of cholesterol elimination. In normocholesterolemic rats, the main effect of fenofibrate is an inhibition of cholesterol biosynthesis.

Fenofibrate has no anti-inflammatory, cardiovascular, respiratory, CNS, autonomic nervous system, or other basal metabolism activities.

Clinical Pharmacology

Uricosuric action

Fenofibrate decreased the plasma uric acid levels in normal as well as hyperuricemic subjects. In a study involving 10 healthy male volunteers, single doses of 300 mg of fenofibrate, non-micronized formulation, were compared to benzbromarone. A uricosuric action was observed with both drugs. During a 14-day study in hyperlipidemic patients, a 28 % decrease in plasma uric acid concentration was observed less than four days after the onset of treatment with 300 mg/day of fenofibrate, non-micronized formulation. This effect remained constant until the end of the study. An additional study conducted in healthy volunteers confirmed the rapid onset of the fenofibrate-induced hypouricemic effect and demonstrated the increased capability of the kidneys under these conditions to eliminate uric acid without damage to the proximal tubules.

Effect on lithogenic index

By virtue of structural similarity to other fibrates, fenofibrate might be suspected of increasing the risk of gallstones as a result of increased cholesterol excretion via the bile.

The biliary lithogenic index in fenofibrate-treated patients was evaluated. In most studies, the lithogenic index was shown to be increased but the effect of fenofibrate was not marked and the degree of significance varied from one study to another. The relative proportions of bile lipids were also affected by fenofibrate treatment.

It is not known how fenofibrate treatment modifies the lipid composition of the bile. Human liver biopsies

Two specific studies have been conducted in hyperlipidemic patients to evaluate the potential hepatocellular toxicity of fenofibrate. Examination of biopsies from liver samples of 38 patients including 28 receiving fenofibrate, non-micronized formulation, over a mean period of approximately 2 years did not show any difference between treated and untreated patients. Peroxisomes were relatively rare, and macroscopic light and electron-microscopic observations revealed no sign of treatment-associated cellular abnormality. A similar study, taking biopsies from 10 patients who had, on average, received fenofibrate, non-micronized formulation, for 9 months, and comparing these with tissue from 13 hyperlipidemic patients who had only received dietary treatment did not show any morphological difference between the two groups or any significant difference in the number or in the size of peroxisomes.

Concomitant administration with ezetimibe: Administration of fenofibrate with ezetimibe is effective in improving serum total-C, LDL-C, Apo-B, TG, HDL-C, and non-HDL-C in patients with mixed hyperlipidemia.

Clinical studies have demonstrated that elevated levels of total-C, low density lipoprotein cholesterol (LDL-C) and apolipoprotein B (Apo B; the major protein constituent of LDL), promote atherosclerosis in humans. In addition, decreased levels of high density lipoprotein cholesterol (HDL-C) are associated with the development of atherosclerosis. Epidemiologic studies have established that cardiovascular morbidity and mortality vary directly with the level of total-C and LDL-C and inversely with the level of HDL-C. Like LDL, cholesterol-enriched triglyceride-rich lipoproteins, including very low density lipoproteins (VLDL), intermediate density lipoproteins (IDL), and remnants, can also promote atherosclerosis. The effects of fenofibrate given with ezetimibe on cardiovascular morbidity and mortality have not been established.

10.3. Pharmacokinetics

Absorption

Absorption of a micronized fenofibrate formulation is low and variable when administered under fasting conditions and increases when given with food. Fenofibrate, given in a micro-coated formulation, requires lower doses (160 mg) to achieve equivalent plasma levels to the micronized (200 mg) formulation. Nanocrystallization of fenofibrate allows for further reduction in the dose (JAMP Fenofibrate E 145 mg tablets), and JAMP Fenofibrate E may be taken without regard to meals, because of optimized product absorption.

Distribution

Fenofibric acid is extensively bound (> 99 %) to plasma albumin. This binding is not saturable.

Metabolism

After oral administration, fenofibrate is rapidly hydrolysed to fenofibric acid, the active metabolite.

Elimination

In man, fenofibric acid is eliminated as the glucuronic acid conjugate and is mainly excreted through the kidney. In man, the elimination half-life of fenofibric acid is about 20 to 24 hours, a value that is not modified after multiple dosing.

In healthy elderly patients (77 to 87 years of age), the terminal half-life is prolonged, but no dose adjustment is required due to unchanged clearance.

Special populations and conditions

• Pediatrics: Safety and effectiveness have not been established in pediatric patients.
• Sex: No gender-related differences in pharmacokinetics and metabolism have been observed.
• Hepatic Insufficiency: No pharmacokinetic studies have been conducted in patients having hepatic insufficiency.

• Renal Insufficiency: In patients with severe renal impairment the rate of clearance of fenofibric acid is greatly reduced, and the compound accumulates during chronic dosage.

  In patients having moderate renal impairment (creatinine clearance of 30 to 60 mL per min.), the oral clearance and oral volume of distribution of fenofibric acid are increased compared to healthy adults (2.1 L/h and 95 L versus 1.1 L/H and 30 L, respectively). Therefore, the dosage of JAMP Fenofibrate E should be minimized to 48 mg in patients who have moderate renal impairment.

  If no low dose is available, then fenofibrate is not recommended.

  In patients with severe renal impairment (creatinine clearance < 30ml/min), fenofibrate is contraindicated.

• Storage, Stability, and Disposal

Store at room temperature, 15-30°C.

Part 2: Scientific Information

13. Pharmaceutical Information

Drug Substance

Non-proprietary name of the drug substance(s):

fenofibrate

Chemical name:

2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoic acid 1-methylethyl ester.

Molecular formula and

molecular mass:

C20H21ClO4

360.8 g/mol

Structural formula:

Physicochemical properties:

Description:

Fenofibrate is a white or almost white, crystalline powder.

Melting point:

79 to 82°C.

Solubilities:

Fenofibrate is practically insoluble in purified water, very soluble in methylene chloride, slightly soluble in ethanol (96 %).

14. Clinical Trials

14.1. Clinical Trials by Indication

Study design and study population

The activity of fenofibrate has been evaluated in more than 150 clinical trials performed in the U.S., Canada and Europe. The majority of these were conducted with fenofibrate, micronized formulation (LIPIDIL Micro), at a daily dose of 200 mg.

Specific clinical studies were performed with fenofibrate, micronized formulation (LIPIDIL Micro).

The first clinical trial followed a double-blind, parallel group versus placebo design. One hundred and eighty-nine patients (Type IIa; 120 and Type IIb; 69) were randomized in three groups: placebo, 200 mg micronized fenofibrate and 3 x 100 mg non-micronized fenofibrate. The ages of the patients ranged from 18 to 75 years. The intent-to-treat analysis indicated an efficacy level after 3 months (as assessed by the number of patients who experienced a cholesterol reduction > 15%) which was significantly greater in the micronized fenofibrate group (71.9%) than in the placebo group (14.8%). Micronized fenofibrate treatment was significantly more active than placebo in reducing total cholesterol (-18%), LDL-cholesterol (-22%), triglycerides (-19%) and apolipoprotein B (-24%).

The second clinical trial evaluated the effectiveness of micronized fenofibrate on lipid parameters. Of 131 eligible patients, 94 (31 Type IIa, 23 Type IIb and 40 Type IV) were evaluated for efficacy. Of those with Type IIa and Type IIb, 45.1% and 69.6%, respectively, were classified as good responders for total cholesterol. Of patients with Type IIb and IV, 71.4% and 77.7%, respectively, were considered good responders for triglycerides. After 3 months of treatment, the mean value of total cholesterol was lowered in patients with Type IIa from 311.4 mg/dl to 258.3 mg/dl with a mean decrease of 17 %. In patients with Type IIb, the mean value of total cholesterol was lowered from 328.0 mg/dl to 266.5 mg/dl, with a mean decrease of 18.6 %. The mean value of triglycerides was lowered in patients with Type IIb from 254.8 mg/dl to 165.7 mg/dl with a mean decrease of 34.4 %. In patients with Type IV, the mean value of triglycerides was lowered from 383.8 mg/dl to 231.1 mg/dl with a mean decrease of

37.9 %.

A placebo-controlled, double-blind study was also performed in 418 patients with type 2 diabetes: The Diabetes Atherosclerosis Intervention Study (DAIS). The patients were randomized to either micronized fenofibrate 200 mg once daily or to placebo for an average of 38 months. The main objectives were to determine the safety of 200 mg fenofibrate, micronized formulation, in a population of type 2 diabetic patients and to measure angiographic responses by quantitative coronary angiography (QCA). Male (73%) and female patients were included in the study. They presented with adequate glycemic control, total cholesterol/high density lipoprotein cholesterol ratio ≥4, and either low-density lipoprotein cholesterol (LDL-C) from 3.5 to 4.5 mmol/l with triglycerides (TG) ≤ 5.2 mmol/l, or TG from 1.7 to 5.2 mmol/l with LDL C ≤ 4.5 mmol/l. An adequate QCA with previous CABG or PTCA or at least one coronary segment with a minimal detectable stenosis was also required.

Study results

The primary efficacy parameter was the mean segment parameter, averaged per patient, to test a null hypothesis of no difference between fenofibrate- and placebo-treated patients. Additional secondary angiographic efficacy parameters were also analyzed.

The angiographic results showed that the primary endpoint (mean segment diameter per patient) did not reach statistical significance and the change from baseline was not clinically meaningful (see following Table 6). The change in mean segment diameter was minimal in both groups over the treatment period, with no statistical difference between groups.

Table 6 – DAIS study: Mean coronary angiogram values (± S.D.) averaged per patient and per segment at baseline and at the end of study (ITT population)

*p-values for Student’s t test and for covariance analysis to compare treatment groups, respectively, at baseline and at the end of the study (last available value on treatment). Statistical significance was established at 0.025.

The changes in lipid levels were also monitored in the type 2 diabetic patients included in the DAIS study. The major lipid values at baseline and at the end of the study are shown in the following Table 7 for both the fenofibrate- and placebo-treated groups.

Table 7 – DAIS study: Mean major lipid values (±S.D.) at baseline and at the end of the study (ITT population)

*p-values for Student’s t test and for covariance analysis to compare treatment groups at baseline and at the end of the study (last available value on treatment)

Co-administration with Ezetimibe

In a multicenter double-blind, placebo-controlled, clinical study in patients with mixed hyperlipidemia, 625 patients were treated for up to 12 weeks and 576 for up to 1 year. Patients with an LDL-C ≥

3.4mmol/L [130 mg/dL] and ≤ 5.7 mmol/L [220 mg/dL] (for non-diabetics) or ≥ 2.6 mmol/L [100 mg/dL] and ≤ 4.7 mmol/L [180 mg/dL] (for diabetics), and with TG ≥ 2.3 mmol/L [200 mg/dL] and≤ 5.7 mmol/L [500 mg/dL] were randomized to receive placebo, ezetimibe alone, 160 mg fenofibrate alone, or ezetimibe and 160 mg fenofibrate. In general, the groups were balanced with regard to body weight, sex, age, race and baseline lipids; at entry into the study the mean LDL-C was 4.2 mmol/L [161 mg/dL] while the mean age was 54 years and 56% were male.

Ezetimibe co-administration with fenofibrate significantly lowered total-C, LDL-C, Apo B, and non-HDL-C compared to fenofibrate or ezetimibe administration alone. The percent decrease in TG and percent increase in HDL-C for ezetimibe co-administered with fenofibrate were comparable to those for fenofibrate administered alone (see Table 8 below).

Table 8 – Response to ezetimibe and fenofibrate initiated concurrently in patients with mixed hyperlipidemia (Mean^a % change from untreated baseline^b at 12 weeks)

^aFor triglycerides, median % change from baseline

^bBaseline- on no lipid-lowering drug

Improvements in lipid endpoints after 1 year of treatment were consistent with the 12-week data displayed above.

14.2. Comparative Bioavailability Studies

A randomized, double-blinded, two-period crossover, single-dose (1 × 48 mg) bioequivalence study of ^PrJAMP Fenofibrate E (JAMP Pharma Corporation) and ^PrLIPIDIL EZ^® (BGP Pharma ULC) was conducted in healthy adult human male subjects under fasting conditions. A summary of the bioavailability data from the 24 subjects that were included in the pharmacokinetics and statistical analyses is presented in the following table.

SUMMARY TABLE OF THE COMPARATIVE BIOAVAILABILITY DATA

¹ JAMP Fenofibrate E (fenofibrate) tablets, 48 mg (JAMP Pharma Corporation, Canada).

^{2 Pr}LIPIDIL EZ^® (fenofibrate) tablets, 48 mg (BGP Pharma ULC).

³ Expressed as the median (range) only

⁴ Expressed as the arithmetic mean (CV%) only

A randomized, double-blinded, two-period crossover, single-dose (1 × 48 mg) bioequivalence study of ^PrJAMP Fenofibrate E (JAMP Pharma Corporation) and ^PrLIPIDIL EZ^® (BGP Pharma ULC) was conducted in healthy adult human male subjects under fed conditions. A summary of the bioavailability data from the 24 subjects that were included in the pharmacokinetics and statistical analyses is presented is presented in the following table.

SUMMARY TABLE OF THE COMPARATIVE BIOAVAILABILITY DATA

¹ JAMP Fenofibrate E (fenofibrate) tablets, 48 mg (JAMP Pharma Corporation, Canada).

^{2 Pr}LIPIDIL EZ^® (fenofibrate) tablets, 48 mg (BGP Pharma ULC).

³ Expressed as the median (range) only

⁴ Expressed as the arithmetic mean (CV%) only

A randomized, double blinded, two-period crossover, single-dose (1 x 145 mg) bioequivalence study of ^PrJAMP Fenofibrate E (JAMP Pharma Corporation) and ^PrLIPIDIL EZ^® (BGP Pharma ULC) was conducted in healthy adult human male subjects under fasting conditions. A summary of the bioavailability data from the 21 subjects that were included in the pharmacokinetic and statistical analyses is presented in the following table:

SUMMARY TABLE OF THE COMPARATIVE BIOAVAILABILITY DATA

¹ JAMP Fenofibrate E (fenofibrate) tablets, 145 mg (JAMP Pharma Corporation, Canada).

^{2 Pr}LIPIDIL EZ^® (fenofibrate) tablets, 145 mg (BGP Pharma ULC).

³ Expressed as the median (range) only

⁴ Expressed as the arithmetic mean (CV%) only

A randomized, double blinded, two-period crossover, single-dose (1 x 145 mg) bioequivalence study of ^PrJAMP Fenofibrate E (JAMP Pharma Corporation) and ^PrLIPIDIL EZ^® (BGP Pharma ULC) was conducted in healthy adult human male subjects under fed conditions. A summary of the bioavailability data from the 22 subjects that were included in the pharmacokinetic and statistical analysis is presented in the following table:

SUMMARY TABLE OF THE COMPARATIVE BIOAVAILABILITY DATA

^{1 Pr}JAMP Fenofibrate E (fenofibrate) tablets, 145 mg (JAMP Pharma Corporation, Canada).

^{2 Pr}LIPIDIL EZ^® (fenofibrate) tablets, 145 mg (BGP Pharma ULC).

³ Expressed as the median (range) only

⁴ Expressed as the arithmetic mean (CV%) only

16. Non-Clinical Toxicology

All toxicology studies were performed using fenofibrate, non-micronized formulation.

General toxicology Acute toxicity

Results from studies in mice, rats, hamsters and dogs indicate a low toxicity for fenofibrate with the highest administered doses (3200 to 24000 mg/kg), resulting in no deaths over the 7-day observation period. Autopsy findings were negative.

Chronic toxicity studies

Rats with normal or high cholesterol diet were treated for 7 days by gavage with fenofibrate at 0, 3, 10, 30, 100 and 300 mg/kg/day or clofibrate at 20, 60, 200 and 600 mg/kg/day. AST levels were raised in treated rats but ALT levels remained within the normal range for rats on normal diet and were only slightly elevated in rats on the high cholesterol diet. Dose-related hepatomegaly and proliferation of peroxisomes occurred, at doses above 30 mg/kg/day. In a second but similar study of drug metabolising enzymes, rats were treated daily by gavage for 7 days with fenofibrate at 0 or 100 mg/kg or clofibrate 200 mg/kg. The absence of significant change in the parameters measured suggests that the mechanisms resulting in hepatomegaly caused by both fibrates had little effect on cell organelles involved in drug metabolism and protein synthesis. In a third study in rats, oral doses of fenofibrate (0 to 1000 mg/kg) were given for 3 months. Depression of blood lipids was seen at all dose levels. AST and ALT values were increased at 500 and 1000 mg/kg. Hepatomegaly was a consistent finding at all dose-levels reaching a maximum of 78 % increase in weight compared to controls but appeared to regress rapidly. There were no other significant findings in the histological examination.

In a three-month oral nonclinical study in the rat species with fenofibric acid, the active metabolite of fenofibrate, toxicity for the skeletal muscles (particularly those rich in type I -slow oxidative- myofibres) and cardiac degeneration, anemia and decreased body weight were seen at exposure levels ≥50- fold the human exposure for the skeletal toxicity and >15 fold for the cardiomyotoxicity. Reversible ulcers and erosions in the gastro-intestinal tract occurred in dogs treated during 3 months at exposures approximately 7-fold the clinical AUC.

A 7-month study in dogs with 50 and 100 mg/kg/day and a 24-month study with 25 mg/kg/day were carried out. None of the dogs died but there was substantial weight loss associated with cholelithiasis and some interstitial nephritis. No important changes were observed in the biological parameters.

Livers were apparently normal.

Fenofibrate (0, 12, 50 or 500 mg/kg/day) or clofibrate (200 mg/kg/day) was administered in the food of Rhesus monkeys for 12 months. No fenofibrate-related effect with regard to toxicity was noted in any of the test groups during the study. No evidence of compound-related histomorphologic alterations was present in the animals sacrificed. The Rhesus monkey resembles man where biopsy studies show no signs of peroxisome proliferation during up to 2 years of fenofibrate treatment.

Genotoxicity

Gene mutations: In vitro tests for mutagenicity with either fenofibrate or fenofibric acid in the presence or absence of activating rat or human microsomal enzyme preparations, have all given negative results. Thus, fenofibric acid was without effect on gene mutation frequency in bacteria (Ames), yeast and mouse lymphoma cells in culture.

In a second mouse lymphoma cell comparative study, there was no response to clofibric acid while some increased response to fenofibric acid at the highest concentration used was discounted due to poor relative growth. Similar activity was seen with gemfibrozil at toxic concentrations in the absence of metabolic activation. In conclusion, all three fibrates were found to be non-mutagenic on the protocol criteria, both in the absence and presence of metabolic activation.

Chromosome aberrations: Some trace of increased but not significant incidence of aberrations was seen in an in vitro mouse lymphoma cell multiple end point assay.

Chromosome aberrations as such were not seen in a more recent comparative in vitro study with CHO cells when testing clofibric acid and gemfibrozil as well as fenofibric acid. However, clofibric acid did have a marginal effect in increasing sister chromatid exchange frequency.

The absence of excision repair in human originated HeLa cells incubated with a wide range of concentrations of fenofibric acid with or without S9 reaffirmed the essentially non-genotoxic nature of the product.

Direct effects on DNA: The ability to bind covalently to target organ DNA is a property common to chemical substances which act by direct initiation of the carcinogenic process at the nuclear level. This type of genotoxic activity can be studied in vivo by DNA assay in rodents treated with the radiolabeled drug.

Although binding of fenofibric and clofibric acids to proteins was readily observed, no binding to DNA was demonstrated after oral administration of C¹⁴-labeled fenofibric or clofibric acid. The data therefore exclude somatic mutations as responsible for the known hepatocarcinogenic activity of these fibrates in rodents.

In a second in vivo test the effects of fenofibric acid were compared with those of clofibric acid and gemfibrozil on DNA synthesis in mouse testicular tissue, as measured by the incorpor¬ation of ³H thymidine. Any response is representative of changes in DNA synthesis in any testicular cells such as germ, Sertoli, Leydig or interstitial cells undergoing scheduled or unscheduled synthesis.

Both fenofibric acid and gemfibrozil caused modest increases in thymidine incorporation above control values. Clofibrate caused some inhibition of the incorporation of thymidine into DNA at the two lowest doses with a small increase at the highest. No positive control substance was used but it would be assumed that, for example, genotoxic alkylating agents might cause a decrease in incorporation due to an inhibition of DNA synthesis. Such inhibition or cell cycle delay is well known for such agents.

The increase in DNA synthesis as observed in mouse testicular tissue with fenofibric acid and gemfibrozil is difficult to evaluate in the absence of a positive control or historical data for this recently developed test, nevertheless such an effect might be anticipated of such agents which are known to cause peroxisome proliferation and which produce increased cell turnover. The occurrence of increased cell turnover would be in keeping with a non-genotoxic but promoting mode of such compounds in mice.

In a rat primary hepatocyte unscheduled DNA synthesis (UDS) assay in vitro, gemfibrozil, clofibric acid and fenofibric acid showed a negative response. None caused nuclear labeling significantly different from the control and no dose-related trends were evident.

Cell growth or malignant transformation in vitro: fenofibric acid was without effect on growth or malignant transformation of cultured mammalian cell lines.

Carcinogenicity

Five rodent studies have shown that target organs for tumorigenic effects of fenofibrate are liver, pancreas and testes.

Mice showed increased liver weight with intrahepatic cholestasis and some degenerative changes but not liver tumors with 50 mg/kg/day for 22 months.

Dose-related increases in liver and kidney weight were seen in mice treated with 10 to 200 mg/kg/day of fenofibrate for 80 weeks.

When given at a dose of 200 mg/kg/day, both fenofibrate and clofibrate produced gross hepatomegaly associated with cholestasis and occasional cholangitis and periportal fibrosis. Neoplastic lesions were confined to the liver with significant increases in hepatocellular carcinoma at the high dose of fenofibrate in both sexes. Hepatocellular adenomas were also increased in males. In clofibrate-treated mice there was an excess of hepatic adenomas in females but not in males.

Both fenofibrate and clofibrate were found to be associated with an increased incidence of hepatocellular hypertrophy, lobular dysplasia and Kupffer cell pigmentation in another long-term toxicity study (93 weeks) on mice. In both sexes the incidence of total hepatic neoplasms and carcinomas was significantly increased by the high dose of fenofibrate (200 mg/kg). At the intermediate dose (60 mg/kg) the combined tumor incidence was almost significant in males but not in females, while incidence of carcinomas was not significantly increased in males and absent in females. Also, clofibrate (400 mg/kg) significantly increased the total tumor incidence but not carcinomas in males; females were unaffected.

Rats, which received fenofibrate (0, 10, 45 or 200 mg/kg/day) or clofibrate (200 mg/kg/day) mixed with their diet for a 2-year period showed no significant differences in mortality over the study period.

Significant increases in incidences of hepatocellular carcinoma were found in the high dose fenofibrate group of animals of both sexes, in mid-dose fenofibrate males, and in clofibrate treated males. Mid-dose fenofibrate males and clofibrate-treated males and females also showed significantly increased incidence of hepatocellular adenomas. Well-differentiated pancreatic acinar cell carcinomas and adenomas were increased in a dose-related manner in the fenofibrate treated males, and higher incidences were also evident in the clofibrate males.

The chronic toxicity and carcinogenicity of fenofibrate was further studied in rats (0, 10 and 60 mg/kg/day) in order to compare treatment-related responses with those produced by clofibrate (400 mg/kg/day) and gemfibrozil (250 mg/kg/day) during 117 weeks of treatments. The absolute and relative weights of the liver were increased in all treatment groups except with 10 mg/kg fenofibrate. Although comparatively low, an incidence of hepatocellular carcinoma was observed in gemfibrozil-treated rats, and neoplastic nodules were also found in the livers of 50 % of the males, which survived up to the termination of the study. Fewer neoplastic nodules were seen in the clofibrate-treated rats but these animals had a high incidence of hepatocellular carcinoma at termination. A significantly increased incidence of pancreatic acinar cell adenoma was seen in the 60 mg/kg fenofibrate males, while this increase in females was not significant. A significant increase in acinar adenoma and a slight increase in acinar carcinoma occurred with clofibrate (400 mg/kg) and some adenomas were seen in gemfibrozil-treated rats. There was some excess of benign interstitial cell tumors of the testes in all treatment groups except the group that received 10 mg/kg of fenofibrate.

Reproductive and developmental toxicology

There was no evidence of any increase in malformation frequency in mice, rabbits and rats after administration of fenofibrate compared to that seen in controls. Examination of offspring from fenofibrate-treated dams and those having received clofibrate did not disclose any significant abnormalities when compared to offspring from the controls.

With the highest dose levels at which the mothers were adversely affected, there was evidence of embryotoxicity in rats and rabbits.

17. Supporting Product Monographs

1. 1. ^PrLIPIDIL EZ® (tablets, 48 mg and 145 mg), Control 298755, Product Monograph, BGP Pharma ULC. 2025-12-05